Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Heim

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Identification of 5-HT<sub>2A</sub> Receptor Signaling Pathways Responsible for Psychedelic PotentialJason Wallach, Andrew B Cao, Maggie M Calkins, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
The Lancet. Neurology|September 22, 2023
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trialPedro M Machado, Michael P McDermott, Thomas Blaettler, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Biorxiv : the Preprint Server for Biology|August 14, 2023
Identification of 5-HT<sub>2A</sub> Receptor Signaling Pathways Responsible for Psychedelic PotentialJason Wallach, Andrew B Cao, Maggie M Calkins, et al.
Muscle & Nerve|November 8, 2024
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosisSalman Bhai, Todd Levine, Dan Moore, et al.
The Lancet. Neurology|September 22, 2023
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trialPedro M Machado, Michael P McDermott, Thomas Blaettler, et al.
Pageof 2